The Old Diagnosis
Revenue decelerates. Board asks questions. VP Sales says the product is not competitive. VP Product says sell what we built. CEO fires the VP Sales, waits six months, repeats.
For most of B2B history, this pattern usually meant one thing: sales execution problem. Post product-market fit, the fix was upgrading the sales team. Get real closers, tighten the funnel, kill vanity metrics. Revenue would re-accelerate.
That story is still true. A great CRO can still double sales if your reps are mediocre and your best leads are going to your worst closers.
What Changed
The product was a constant. You shipped a major release every 12 to 24 months. A customer evaluating in January saw roughly the same thing in December. Sales and marketing became the primary lever because the product barely moved.
That world is gone.
In 2026, products get stale in months, not years. AI infrastructure alone: Claude is 100x more capable than 12 months ago. If you are building on AI, your product can go from cutting-edge to outdated in a quarter. Even if you are not building AI products, your competitors probably are. They are shipping faster, adding agentic capabilities, rethinking entire workflows.
The product itself has become the most volatile variable in the growth equation. It used to be the constant. Now it is the thing most likely to be the root cause when growth slows.
The New Diagnostic
When growth slows in 2026, run this in order:
Competitive position check. Are you as differentiated, as capable, as modern as you were a year ago? If two competitors shipped major AI-native features and you have not, that is your answer. Not sales.
Win rate analysis. Are you losing more head-to-head deals? If losses are concentrated against one or two vendors who shipped big product updates, that is a product problem wearing a sales mask.
Release velocity. If you are on a 12-month release cycle and competitors are shipping weekly, your sales team is fighting with one hand tied.
Execution check. If your product is genuinely competitive, win rates are stable, and close rates per rep are just low, then yes, it is a sales problem.
What This Means for Sales Leaders
A great VP Sales still matters enormously. The classic playbook still works. It is just no longer sufficient. Today, when a new CRO walks in, the product might already be less competitive than when the last CRO started. Win rates might be declining not because reps forgot how to sell, but because the product is falling behind.
In slower-growth environments like ANZ in 2026 (weaker GDP, softer business confidence, tighter budgets), this distinction matters more. Longer sales cycles and conservative spending make it harder to separate sales execution from product or ROI issues. Boards scrutinize pipeline conversion and churn more aggressively, which often leads to sales leadership turnover.
But replacing a CRO will not fix a product gap. The question to ask first: has the product kept pace, or are we asking sales to close deals with ammunition that is already outdated?
Source: SaaStr, ANZ Research market context.